About si bone inc - SIBN
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.
SIBN At a Glance
SI-BONE, Inc.
471 El Camino Real
Santa Clara, California 95050
| Phone | 1-408-207-0700 | Revenue | 200.93M | |
| Industry | Medical Specialties | Net Income | -18,904,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 20.186% | |
| Fiscal Year-end | 12 / 2026 | Employees | 376 | |
| View SEC Filings |
SIBN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.216 |
| Price to Book Ratio | 4.848 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -44.446 |
| Enterprise Value to Sales | 3.663 |
| Total Debt to Enterprise Value | 0.05 |
SIBN Efficiency
| Revenue/Employee | 534,375.00 |
| Income Per Employee | -50,276.596 |
| Receivables Turnover | 6.606 |
| Total Asset Turnover | 0.857 |
SIBN Liquidity
| Current Ratio | 8.549 |
| Quick Ratio | 7.208 |
| Cash Ratio | 5.848 |
SIBN Profitability
| Gross Margin | 79.571 |
| Operating Margin | -11.114 |
| Pretax Margin | -9.408 |
| Net Margin | -9.408 |
| Return on Assets | -8.062 |
| Return on Equity | -10.975 |
| Return on Total Capital | -8.825 |
| Return on Invested Capital | -9.076 |
SIBN Capital Structure
| Total Debt to Total Equity | 20.666 |
| Total Debt to Total Capital | 17.126 |
| Total Debt to Total Assets | 15.379 |
| Long-Term Debt to Equity | 20.134 |
| Long-Term Debt to Total Capital | 16.686 |